Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Clinical trial NCT01212094 · TERMINATED
Trial details
- NCT number
- NCT01212094
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-09-01
- Primary completion
- 2015-12-01
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.